Use of cyclosporine microemulsion (Neoral) in de novo and stable renal transplantation: clinical impact, pharmacokinetic consequences and economic benefits. Canadian and International Neoral Study Groups.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Transplantation Proceedings

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 8769183
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Economic analysis of Sandimmune Neoral in Canada in stable renal transplant patients.

  1995cited by this paper
• CYCLOSPORINE PHARMACOKINETICS AND VARIABILITY FROM A MICROEMULSION FORMULATION—A MULTICENTER INVESTIGATION IN KIDNEY TRANSPLANT PATIENTS

  1994cited by this paper
• Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation.

  1994cited by this paper
• Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation

  1993cited by this paper
• Cyclosporine Monitoring in Renal Transplantation: Area Under the Curve Monitoring Is Superior to Trough‐Level Monitoring

  1989cited by this paper
• Clinical Pharmacokinetics of Cyclosporin

  1986cited by this paper

• New developments in immunosuppressive therapy for heart transplantation

  2009cites this paper
• Changements posologiques engendrés par le monitorage de la cyclosporine deux heures après la prise chez les patients greffés cardiaques

  2007cites this paper
• Cyclosporine trough (C0) and 2-hour postdose (C2) levels: which one is a predictor of graft loss?

  2007cites this paper
• Suitable whole blood levels 2 hours after neoral in liver transplant patients: experiences at a single center.

  2006cites this paper
• Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.

  2005cites this paper
• History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion.

  2004cites this paper
• Evolution of the therapeutic drug monitoring of cyclosporine.

  2004cites this paper
• Conversion from once-daily Sandimmune cyclosporine to once-daily Neoral in renal transplant patients.

  2000cites this paper
• Neoral use in the liver transplant recipient.

  2000cites this paper
• Microemulsion cyclosporine postmarketing surveillance in renal transplant recipients: multicenter study in Korea.

  2000cites this paper
• Validity of open labeled versus blinded trials: a meta-analysis comparing Neoral and Sandimmune.

  1999cites this paper
• The evaluation of the safety and tolerability of two formulations of cyclosporine: neoral and sandimmune. A meta-analysis.

  1999cites this paper
• Influence of drug formulation on utilization and outcomes: Neoral and monitoring by sparse sample area under the curve.

  1999cites this paper
• Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation.

  1999cites this paper
• Current opinions on therapeutic drug monitoring of immunosuppressive drugs.

  1999cites this paper
• Considerations concerning generic formulations of immunosuppressive drugs.

  1999cites this paper
• Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.

  1998cites this paper
• Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method.

  1998cites this paper
• Evaluation of the safety and tolerability of Neoral and Sandimmune: a meta-analysis.

  1998cites this paper
• Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation, using a dose-adjusted method.

  1998cites this paper
• A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.

  1998cites this paper
• Comparison of renal transplant outcome with Neoral versus Sandimmune as part of an initial triple therapy regimen.

  1998cites this paper
• Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997).

  1998cites this paper
• Economic relevance of cyclosporine microemulsion in kidney transplanted patients.

  1998cites this paper
• Safety and effectiveness of microemulsion cyclosporine in renal allograft recipients: 1-year follow-up study.

  1998cites this paper
• Pretransplant test-dose pharmacokinetic profiles: cyclosporine microemulsion versus corn oil-based soft gel capsule formulation.

  1998cites this paper
• Diminution du risque de rejet chronique et de variabilité de l’absorption avec Néoral® par rapport à Sandimmun®

  1997cites this paper